Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "【Order On Telegram: @Chem2Door】Where To Buy Lunesta In San Diego,.7093"

Looking for quality documents?
corporate icon
Knowledge Base
Find product resources, videos, and articles
corporate icon
SpectraPor®   •   SpectraFlo®   •   Membranes   •   Tubing
corporate icon
TangenX® Hardware
TangenX® hardware are designed for use with TangenX® filter cassettes and disc membranes for tangential flow filtration.
corporate icon
TangenX® SIUS® Gamma TFF Devices
With the performance and efficiency of SIUS® Cassettes, SIUS Gamma Devices come as a convenient, fully assembled, closed, and sterile system.
corporate icon
KF Comm 2 Software
Proprietary, menu-driven software is optimized for use with KrosFlo® KR2i, KrosFlo® KMPi and KrosFlo® FS Tangential Flow Filtration Systems.
corporate icon
Polysorbate Analysis
Challenge: Surfactant degradation is a known stability issue, but often goes undetected in downstream processing. Our Solution: In-line absorbance monitoring ensures polysorbate levels are within spec, protecting protein formulations.
external link icon
Repligen Acquires Bioprocessing Business of Refine Technology
- Expands Portfolio of Products to Improve Efficiencies in Biologic Drug Manufacturing - - Company Updates 2014 Financial Guidance - - Conference Call and Webcast Today at 9:00 a.m. EDT - WALTHAM, Mass., June 3, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that it has acquired the business of Refine Technology ("Refine"), including Refine's Alternating Tangential Flow ("ATF") System, a market-leading device used to significantly increase product yield during the fermentation step of the biologic drug manufacturing process. The acquisition strengthens Repligen's bioprocessing business by adding a profitable and highly complementary product line while expanding the Company's direct sales presence worldwide. Repligen has entered into a definitive agreement effective June 2, 2014 to purchase Refine's business for a combination of $20.5 million in cash and 215,285 shares of Repligen common stock, for total upfront consideration of approximately $24.5 million.
external link icon
Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
external link icon
Repligen Releases Inaugural Sustainability Report
Sets Baseline and Provides SASB, GRI Core and SDG Disclosures WALTHAM, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today released its inaugural sustainability report, available on the Company’s website . Repligen’s 2020 Sustainability Report provides an overview of the Company’s environmental, social and governance (ESG) performance in 2020 and into 2021, and provides disclosures aligned to three key reporting frameworks; the Value Reporting Foundation’s SASB Medical Equipment and Supplies Standard, the Global Reporting Initiative (GRI) Standards Core option, and the United Nations (UN) Sustainable Development Goals (SDGs) as informed by the Company’s materiality assessment. As a participant of the United Nations Global Compact (UNGC) since July 2020, this report also serves to fulfill Repligen’s first Communication on Progress (COP) commitment.

The report is built on four pillars that reflect Repligen’s ESG priorities – Principles, People,
news icon
More cells, faster.
Simplify and intensify upstream bioprocessing. The XCell® ATF System, in single-use or stainless steel format, delivers high cell retention.
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support